Neutrophil-Lymphocyte Ratio Proves Possible Biomarker for ED
|
By LabMedica International staff writers Posted on 30 May 2019 |
|
Image: A blood film showing typical red and white blood cells (Photo courtesy of Sherri Wick).
Erectile dysfunction is described as the impotency to obtain or sustain an erection sufficiently in order to enable convincing sexual intercourse. Erectile dysfunction (ED) is estimated to affect about 75% of men over the age of 75 and 20% of men over the age of 20.
The association among many diseases, inflammatory markers and also their roles in the disease etiopathogenesis are important. The literature reveals that emerge and severity of ED are related with markers and mediators of inflammation and endothelial dysfunction.
Urologists at the Ordu University (Ordu, Turkey) and their colleagues evaluated 90 patients with erectile dysfunction (ED) and 94 healthy subjects from their internal medicine and urology clinics. As diagnosis criteria, they used the first five questions of International Index for Erectile Function. The duration of erectile dysfunction was asked and recorded. Height, weight and waist circumference of patients were measured.
The team performed total blood count, sedimentation, C-reactive protein, blood urea nitrogen (BUN), creatine, cholesterol, Low-density lipoprotein cholesterol (LDL-C) and High-density lipoprotein cholesterol (HDL-C) measurements of the patients were recorded. The neutrophil-lymphocyte ratio (NLR) was computed as the total neutrophil count separated by the total lymphocyte count.
The investigators found that there were statistically significant differences in terms of NLR between the control 1.038 (range: 0.507-1.92) and ED 2.38 (1.67.0-3.00) groups. According to the multivariate logistic regression analysis, duration of ED (Cut off: 7.5 month) predicted ED with 78.8% sensitivity and 63.1% specificity (AUC: < 0.001). Moreover, NLR (Cut off: 1.574) predicted ED with 81.8% sensitivity and 67.0% specificity (AUC: < 0.001) according to the multivariate logistic regression analysis.
The authors concluded that that the neutrophil-lymphocyte ratio was higher in patient group than the control group, and that the neutrophil-lymphocyte ratio (NLR) predicted ED and it might be helpful in diagnosing erectile dysfunction. The study was published on May 5, 2019, in the Urology Journal.
Related Links:
Ordu University
The association among many diseases, inflammatory markers and also their roles in the disease etiopathogenesis are important. The literature reveals that emerge and severity of ED are related with markers and mediators of inflammation and endothelial dysfunction.
Urologists at the Ordu University (Ordu, Turkey) and their colleagues evaluated 90 patients with erectile dysfunction (ED) and 94 healthy subjects from their internal medicine and urology clinics. As diagnosis criteria, they used the first five questions of International Index for Erectile Function. The duration of erectile dysfunction was asked and recorded. Height, weight and waist circumference of patients were measured.
The team performed total blood count, sedimentation, C-reactive protein, blood urea nitrogen (BUN), creatine, cholesterol, Low-density lipoprotein cholesterol (LDL-C) and High-density lipoprotein cholesterol (HDL-C) measurements of the patients were recorded. The neutrophil-lymphocyte ratio (NLR) was computed as the total neutrophil count separated by the total lymphocyte count.
The investigators found that there were statistically significant differences in terms of NLR between the control 1.038 (range: 0.507-1.92) and ED 2.38 (1.67.0-3.00) groups. According to the multivariate logistic regression analysis, duration of ED (Cut off: 7.5 month) predicted ED with 78.8% sensitivity and 63.1% specificity (AUC: < 0.001). Moreover, NLR (Cut off: 1.574) predicted ED with 81.8% sensitivity and 67.0% specificity (AUC: < 0.001) according to the multivariate logistic regression analysis.
The authors concluded that that the neutrophil-lymphocyte ratio was higher in patient group than the control group, and that the neutrophil-lymphocyte ratio (NLR) predicted ED and it might be helpful in diagnosing erectile dysfunction. The study was published on May 5, 2019, in the Urology Journal.
Related Links:
Ordu University
Gold Member
Hybrid Pipette
SWITCH
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Laboratory Software
ArtelWare
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more